论文部分内容阅读
目的:探讨阿替普酶治疗急性脑梗死的疗效及安全性。方法:选取2016年2月-2017年2月我院收治的100例急性脑梗死患者作为此次研究对象,把治疗方案的不同作为分组依据,将全部患者均分成对照组和观察组。对照组患者接受常规治疗,观察组患者则在此基础之上接受阿替普酶药物治疗,对比两组患者在急性脑梗死治疗效果和安全性方面的差异。结果:实验组的治疗总有效率以及安全性明显高于对照组,两组差异具备统计学意义(P<0.05)。结论:阿替普酶在急性脑梗死患者的治疗当中有着显著效果,具有疗效确切、安全、可靠等优势,具有极大的临床推广以及药用价值。
Objective: To investigate the efficacy and safety of alteplase in the treatment of acute cerebral infarction. Methods: A total of 100 patients with acute cerebral infarction admitted to our hospital from February 2016 to February 2017 were selected as the study subjects. The differences of treatment regimens were used as group basis, and all patients were divided into control group and observation group. Patients in the control group received routine treatment, while patients in the observation group received alteplase on this basis. The differences between the two groups in the therapeutic effect and safety of acute cerebral infarction were compared. Results: The total effective rate and safety of the experimental group were significantly higher than that of the control group, with statistical significance (P <0.05). CONCLUSION: Alteplase has a significant effect in the treatment of patients with acute cerebral infarction and has the advantages of definite curative effect, safety and reliability, and has great clinical promotion and medicinal value.